Table N-17, Sleep disturbance outcomes by age subgroups - Menopausal Symptoms: Comparative Effectiveness of Therapies

Warning: The NCBI web site requires JavaScript to function. more...

Trial	Outcome	Subgroup	Treatment	N	Results
Brunner, 2005, United States	Mean change in WHI sleep score	Age 50-54 with MSVS	Placebo	157	0.53 (SD: 4.6)

			0.625 mg CEE	165	1.4 (SD: 4.6)^a

Hays, 2003, United States	Mean change in WHI sleep score	Age 50-54 with MSVS	Placebo	216	0.8 (SD: 4.6)

			0.625 mg CEE + 2.5 mg MPA	255	1.8 (SD: 4.8)^b

Rigano, 2001, Italy	Percent reporting no insomnia^a	Age 48-50	Placebo	75	29%
		Age 48-50	0.05 mg estradiol	88	80%

		Age 51-53	Placebo	61	46%
		Age 51-53	0.05 mg estradiol	52	62%

		Age 54-56	Placebo	55	17%
		Age 54-56	0.05 mg estradiol	31	100%

a: Unclear whether 100% reported insomnia at baseline
: CEE: conjugated equine estrogen; MPA: medroxyprogesterone acetate ; MSVS: moderate to severe vasomotor symptoms; WHI: Women’s Health Initiative
a: difference from placebo: p=0.11
b: difference from placebo: p=0.02

Menopausal Symptoms: Comparative Effectiveness of Therapies [Internet].

Comparative Effectiveness Reviews, No. 147.

Grant MD, Marbella A, Wang AT, et al.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.